![]() Arm 2: Sotatercept at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, SC every 21 days plus background PAH therapy.Arm 1: Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy. ![]() Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More InformationĮach eligible participant will be randomized in a 1:1 ratio to 1 of the following 2 treatment arms during the double-blind placebo-controlled (DBPC) Treatment Period: Why Should I Register and Submit Results?. ![]()
0 Comments
Leave a Reply. |